BioMarin Pharmaceutical Inc. (BMRN) financial statements (2021 and earlier)

Company profile

Business Address 105 DIGITAL DRIVE
NOVATO, CA 94949
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,0657541,0841,396790593945
Cash and cash equivalents649437494598408397875
Short-term investments41631659079838119670
Restricted cash and investments      2
Receivables448377343261215165191
Inventory, net of allowances, customer advances and progress billings699680531476355272199
Inventory699680531476355272199
Prepaid expense      29
Deferred costs      12
Derivative instruments and hedges, assets      11
Other current assets13013198746260105
Other undisclosed current assets      (69)
Total current assets:2,3421,9422,0562,2071,4221,0901,426
Noncurrent Assets
Property, plant and equipment1,0321,011949897799704524
Long-term investments and receivables28541223638657342698
Long-term investments28541223638657342698
Intangible assets, net (including goodwill)613654689715751881211
Goodwill19619719719719719754
Intangible assets, net (excluding goodwill)417457492518554684157
Derivative instruments and hedges      5
Deposits noncurrent assets      12
Deferred income tax assets1,432549
Other noncurrent assets14212237303340965
Other undisclosed noncurrent assets  461399447220150
Total noncurrent assets:3,5062,7482,3712,4262,6022,6401,065
TOTAL ASSETS:5,8484,6904,4274,6334,0243,7292,490
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:493571437402371393236
Accounts payable      33
Accrued liabilities17316355504398
Employee-related liabilities1651921501411097845
Taxes payable108810865
Other undisclosed accounts payable and accrued liabilities30133921619620426554
Debt 362 36122  
Deferred compensation liability      2
Business combination, contingent consideration, liability  86544653 
Deferred revenue and credits   1
Other undisclosed current liabilities      (3)
Total current liabilities:493933523817439445236
Noncurrent Liabilities
Long-term debt and lease obligation1,075486830814661662658
Long-term debt, excluding current maturities1,075486830814661662658
Liabilities, other than long-term debt17414910619415722130
Deferred tax liabilities, net   144 
Other liabilities114985959424530
Business combination, contingent consideration, liability60514713511533 
Other undisclosed noncurrent liabilities      39
Total noncurrent liabilities:1,2496359361,008818883727
Total liabilities:1,7421,5681,4591,8241,2571,329963
Stockholders' equity
Stockholders' equity attributable to parent, including:4,1063,1222,9682,8092,7662,4011,528
Common stock0000000
Additional paid in capital4,9934,8334,6704,4834,2883,4152,360
Accumulated other comprehensive income (loss)(16)205(23)132127
Accumulated deficit(862)(1,721)(1,694)(1,638)(1,521)(1,022)(850)
Other undisclosed stockholders' equity attributable to parent(10)(10)(13)(14)(14)(14)(10)
Total stockholders' equity:4,1063,1222,9682,8092,7662,4011,528
TOTAL LIABILITIES AND EQUITY:5,8484,6904,4274,6334,0243,7292,490

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues1,8601,7041,4911,3141,117890751
Revenue, net1,3141,117890751
Cost of revenue(524)(359)(315)(242)(210)(152)(130)
Gross profit:1,3361,3451,1761,072907738621
Operating expenses(1,306)(1,371)(1,251)(1,040)(1,138)(668)(753)
Other operating income, net      0
Other undisclosed operating income (loss)(67)(74)(49)(46)(572)(181)39
Operating loss:(37)(100)(124)(15)(803)(111)(93)
Nonoperating income922419222417
Investment income, nonoperating17232315756
Gain on contract termination      10
Foreign currency transaction gain (loss), before tax(8)(1)18(6)14201
Interest and debt expense(29)(23)(44)(43)(39)(38)(37)
Other undisclosed loss from continuing operations before equity method investments, income taxes      (12)
Loss from continuing operations before equity method investments, income taxes:(57)(102)(127)(49)(821)(125)(125)
Loss from equity method investments(0)(1)(1)(1)(1)(1)(1)
Other undisclosed income (loss) from continuing operations before income taxes158(16)14(10)(29) 
Loss from continuing operations before income taxes:(42)(95)(143)(36)(831)(155)(126)
Income tax expense (benefit)9017165(81)201(17)(9)
Net income (loss):859(24)(77)(117)(630)(172)(135)
Other undisclosed net income attributable to parent      1
Net income (loss) available to common stockholders, basic:859(24)(77)(117)(630)(172)(134)
Interest on convertible debt8      
Other undisclosed net loss available to common stockholders, diluted  (1) (3)  
Net income (loss) available to common stockholders, diluted:867(24)(78)(117)(633)(172)(134)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):859(24)(77)(117)(630)(172)(135)
Other comprehensive income (loss)(36)1529(36)(8)(6)22
Comprehensive income (loss):823(9)(48)(153)(638)(178)(112)
Other undisclosed comprehensive income, net of tax, attributable to parent      1
Comprehensive income (loss), net of tax, attributable to parent:823(9)(48)(153)(638)(178)(112)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: